Natco Pharma Ltd. — Capital/Financing Update 2022

Jan 1, 2022

==> picture [451 x 46] intentionally omitted <==

January 1, 2022

Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir

Sub:- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

With reference to the above cited subject and further to our earlier intimation dated 14[th] December,2021 Please find enclose herewith the Press Release under Regulation 30 of SEBI (LODR) Regulations, 2015

This is for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

==> picture [120 x 22] intentionally omitted <==

M. Adinarayana Company Secretary & Vice President (Legal and Corp Affairs

==> picture [451 x 47] intentionally omitted <==

Ref: PR/ 20 /2021-22

Press Release

NATCO completes acquisition of Dash Pharmaceuticals LLC

NATCO Pharma Inc. USA, a wholly owned subsidiary of NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) (“NATCO”), has completed the acquisition of Dash Pharmaceuticals LLC (“Dash”), a New Jersey based entity. Pursuant to this, Dash will become a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO. The acquisition amount paid is US$ 18 million.

Dash is a front-end pharmaceutical sales, marketing and distribution entity in the USA which is expected to have Net Sales of approximately USD 15 million for the financial year ending December 2021.

This acquisition provides NATCO with a platform to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.

---

Forwarded for favour of publication For NATCO Pharma Limited

==> picture [120 x 23] intentionally omitted <==

M Adinarayana Company Secretary & Vice President (Legal & Corp Affairs)